Import from '@/components/mdx'

Jardiance and Levothyroxine: The Drug Interaction Every Woman on Both Medications Should Understand

How These Two Drugs Work and Why Women Often Take Both

Women are disproportionately affected by both hypothyroidism and type 2 diabetes, which is why the combination of levothyroxine and Jardiance (empagliflozin) comes up so often in clinical practice. Hypothyroidism affects roughly 5% of the US population, with women diagnosed at 5 to 8 times the rate of men. Separately, type 2 diabetes affects approximately 37 million Americans, and women with PCOS carry a particularly high lifetime risk, with some estimates placing their odds of developing insulin resistance and T2D at 5 to 10 times that of women without the condition.

What Empagliflozin Does

Empagliflozin is a sodium-glucose cotransporter-2 (SGLT2) inhibitor. It works in the kidney, blocking the SGLT2 protein in the proximal tubule so that glucose is excreted in the urine rather than reabsorbed into circulation. The FDA approved empagliflozin for type 2 diabetes in 2014, and subsequent approvals extended its use to heart failure and chronic kidney disease. Its standard starting dose is 10 mg once daily, with an optional increase to 25 mg once daily for additional glycemic or cardiovascular benefit.

Empagliflozin is metabolized primarily through UGT1A3 and UGT2B7 glucuronidation, not through major CYP450 enzymes. P-glycoprotein (P-gp) plays a minor role in its transport. This metabolic profile matters because levothyroxine also does not depend on CYP metabolism, so a classical enzyme-level drug-drug interaction between the two does not occur.

What Levothyroxine Does

Levothyroxine is synthetic thyroxine (T4). It replaces or supplements the thyroid hormone your body makes. Once absorbed from the gut, T4 is converted peripherally to the active form triiodothyronine (T3), which drives metabolic rate, heart rate, body temperature, cholesterol clearance, and ovarian function. Absorption happens primarily in the jejunum and ileum and is highly sensitive to gut pH, food, calcium, iron, proton pump inhibitors, and other co-administered tablets.

The Real Interaction: Absorption Timing and Gut Environment

There is no direct enzyme-mediated interaction between empagliflozin and levothyroxine. The interaction that matters is indirect, operating through two plausible mechanisms.

Mechanism 1: Competing Tablet Administration

Levothyroxine absorption is notoriously sensitive to anything taken alongside it. Studies published in Thyroid show that co-administration of levothyroxine with calcium carbonate reduces T4 absorption by approximately 20-40%. While empagliflozin does not chelate T4 the way calcium or iron does, taking multiple tablets at the same time still introduces the possibility of physical competition in the gut lumen and altered gastric emptying kinetics. The safest practice is to take levothyroxine first, alone, on an empty stomach, and delay all other morning medications, including Jardiance, by at least 30 to 60 minutes.

Mechanism 2: SGLT2 Effects on Gut Physiology and Metabolic State

SGLT2 inhibitors cause mild glycosuric calorie loss and have documented effects on gut hormone secretion, including GLP-1. There is emerging evidence that changes in gut transit time and intestinal glucose handling could alter the micro-environment in which levothyroxine dissolves. This mechanism has not been directly studied in a randomized controlled trial, and the evidence here is extrapolated from SGLT2 pharmacology rather than a head-to-head levothyroxine interaction study. That gap in the literature is worth naming plainly: no published trial has measured serum free T4 or TSH levels before and after starting empagliflozin in women on stable levothyroxine doses. Clinicians currently rely on mechanistic reasoning and post-marketing pharmacovigilance data.

Mechanism 3: Metabolic Crosstalk Between Glycemic Control and Thyroid Function

Improved glycemic control changes how the body handles thyroid hormone. Poorly controlled diabetes can suppress TSH secretion and alter thyroid-binding globulin (TBG) levels. When empagliflozin substantially improves glucose control, the metabolic milieu shifts, and the levothyroxine dose that was adequate under hyperglycemic conditions may now be slightly different. A 2020 analysis in the Journal of Clinical Endocrinology and Metabolism noted that glycemic improvement with SGLT2 inhibitors modestly influenced thyroid hormone indices in some patients, though the effect sizes were small and not consistently clinically significant.

The WomanRx Dosing-Sequence Framework for Women on Both Drugs:

1. Wake up. Take levothyroxine with a full glass of water. Nothing else.
2. Wait 30-60 minutes (longer if you take calcium or iron later).
3. Eat breakfast if desired.
4. Take empagliflozin 10 mg with or without food.
5. Recheck TSH 6 to 8 weeks after starting empagliflozin or after any dose change to either medication.

Sex-Specific Physiology: Why This Interaction Hits Women Differently

Thyroid Physiology Across the Female Life Cycle

Thyroid function is not static in women. Estrogen increases thyroxine-binding globulin, which raises total T4 levels without necessarily changing free T4. This is why TSH is the preferred monitoring marker rather than total T4. The estrogen connection means that every hormonal transition in a woman's life, from puberty through perimenopause, changes the context in which levothyroxine replacement is interpreted.

During the reproductive years, thyroid autoimmunity (Hashimoto's thyroiditis) is the most common cause of hypothyroidism in women. Managing levothyroxine around SGLT2 therapy during this life stage requires attention to menstrual cycle effects on TSH, which can fluctuate by up to 0.5-1.0 mIU/L across the cycle in women with autoimmune thyroid disease.

PCOS: The Condition That Ties Both Drugs Together Most Often

If you have PCOS, you are statistically more likely to be taking both of these drugs than a woman in the general population. PCOS is associated with a 2-3 fold increased prevalence of autoimmune thyroiditis, and insulin resistance in PCOS accelerates progression toward type 2 diabetes. Empagliflozin is not FDA-approved for PCOS as a primary indication, but it is sometimes prescribed off-label or for co-existing T2D in women with PCOS. If this is your situation, your TSH targets and levothyroxine dosing deserve particularly close attention because the underlying hormonal environment is already more variable.

Perimenopause and Post-Menopause

In perimenopause, TSH levels can be harder to interpret because fluctuating estrogen alters TBG, and symptoms like fatigue, weight gain, brain fog, and irregular cycles overlap substantially between hypothyroidism and perimenopause. Women starting Jardiance during this life stage should insist on a TSH check before starting the drug and a repeat check 8 weeks after. The addition of any new medication during a period of hormonal flux deserves more monitoring, not less.

After menopause, estrogen drops and TBG falls, which can mean that a woman's levothyroxine dose requirement decreases slightly. If she starts empagliflozin at the same time as initiating or changing hormone therapy, the compounding variables make systematic TSH monitoring the only way to know whether her dose is still correct.

Monitoring: What to Track and When

Consistent monitoring is the primary clinical management tool for this combination. There is no dose adjustment table for empagliflozin based on thyroid status, and no dose adjustment formula for levothyroxine based on SGLT2 therapy. The management is empirical: check TSH, adjust levothyroxine, and repeat.

TSH Targets by Life Stage

| Life Stage | TSH Target (mIU/L) | |---|---| | Reproductive years (non-pregnant) | 0.5 to 4.5 | | Trying to conceive | 0.5 to 2.5 | | First trimester of pregnancy | 0.1 to 2.5 | | Second and third trimester | 0.2 to 3.0 | | Perimenopause / post-menopause | 0.5 to 4.5 (individualize) |

These targets are consistent with American Thyroid Association guidelines and should be used as your reference framework rather than lab normal ranges printed on a report.

What Warrants an Unscheduled TSH Check

Get a TSH sooner than your scheduled interval if you notice:

• New or worsening fatigue out of proportion to your activity level
• Unexpected weight gain despite consistent eating patterns and glucose control
• Cold intolerance returning after a period when you felt well
• Menstrual cycle changes (heavier periods, longer cycles, or new irregularity)
• Palpitations or feeling "wired," which may signal over-replacement

Pregnancy and Lactation Safety

This section is required for any article covering medications used by women of reproductive age, because the answers here are materially different from the standard adult management.

Empagliflozin in Pregnancy

Empagliflozin is contraindicated during the second and third trimesters of pregnancy. The FDA label for empagliflozin explicitly warns against use in pregnancy, citing animal data showing adverse renal effects in developing fetuses when the drug was given during the period of nephrogenesis (which corresponds to the human second and third trimester). Human data are limited. No large prospective trial has studied empagliflozin exposure in pregnant women. The current guidance from ACOG does not endorse any SGLT2 inhibitor for use in gestational diabetes or pre-existing diabetes during pregnancy. If you are taking Jardiance and planning a pregnancy, switch to an insulin-based regimen before conception or as soon as you have a positive pregnancy test.

Reliable contraception is required for any woman of reproductive age taking empagliflozin who does not want to become pregnant. This point deserves to be stated plainly in every prescribing conversation.

Levothyroxine in Pregnancy

Levothyroxine is safe in pregnancy, and pregnant women with hypothyroidism need more of it, not less. The levothyroxine dose typically increases by 25-50% during pregnancy, beginning as early as 4 to 6 weeks of gestation. Untreated or under-treated hypothyroidism during pregnancy is associated with miscarriage, preeclampsia, preterm birth, and impaired fetal neurodevelopment. TSH should be checked every 4 weeks through the first 20 weeks of pregnancy in women on levothyroxine replacement. Women with PCOS and autoimmune thyroid disease should discuss pre-conception TSH optimization with their clinician before attempting to conceive.

Lactation

Empagliflozin transfer into human breast milk has not been adequately studied. Animal lactation data exist but are not directly applicable. The FDA label advises against use during breastfeeding due to the potential for renal toxicity in the nursing infant during the period of renal development. Levothyroxine is considered compatible with breastfeeding. Small amounts transfer into breast milk but are not known to cause harm in the nursing infant, and maintaining euthyroidism in the breastfeeding parent is clinically important for both maternal and infant health.

Who This Combination Is Right For (and Not Right For)

Women Who May Benefit Most From Empagliflozin

You are likely a good candidate for empagliflozin alongside your levothyroxine if:

• You have well-controlled hypothyroidism (stable TSH on levothyroxine) plus type 2 diabetes, heart failure, or CKD
• You are post-menopausal with established cardiovascular disease, given the cardiovascular mortality reduction demonstrated in the EMPA-REG OUTCOME trial, where empagliflozin reduced cardiovascular death by 38% versus placebo in women and men with T2D and high CV risk
• You have PCOS with co-existing T2D and you and your clinician have decided empagliflozin is the best glucose-lowering choice at this time
• You can commit to consistent levothyroxine timing and regular TSH monitoring

Women Who Need Special Caution

Exercise more caution or choose an alternative if:

• You are pregnant or planning pregnancy in the near future
• You are breastfeeding
• Your hypothyroidism is unstable (TSH not at target for at least 3 consecutive checks)
• You have difficulty maintaining a consistent morning routine for levothyroxine (consider liquid or soft-gel levothyroxine formulations, which have more consistent absorption kinetics and may be less sensitive to timing errors)
• You have gastroparesis or another condition affecting gut motility, because both drugs can have gut-related effects and levothyroxine absorption becomes even less predictable

Other Jardiance Drug Interactions Worth Knowing

Empagliflozin has a relatively clean drug interaction profile compared to many diabetes medications. Its most clinically significant interactions are pharmacodynamic rather than pharmacokinetic.

• Diuretics: SGLT2 inhibitors have mild diuretic effects. Combined with a loop or thiazide diuretic, the risk of volume depletion and hypotension increases. In perimenopausal and post-menopausal women already on diuretics for hypertension, check blood pressure and kidney function within 4 weeks of starting.

• Insulin and insulin secretagogues (sulfonylureas): Combination increases hypoglycemia risk. The FDA label recommends considering a dose reduction of insulin or sulfonylurea when adding empagliflozin.

• Lithium: Emerging case reports and pharmacological reasoning suggest SGLT2 inhibitors may increase lithium renal clearance through osmotic mechanisms, potentially lowering lithium levels. Women on lithium for bipolar disorder should have lithium levels checked after starting any SGLT2 inhibitor. This interaction has particular relevance for women, given the higher prevalence of bipolar disorder treatment with lithium in women of reproductive age.

• Other levothyroxine absorption disruptors: Calcium carbonate, ferrous sulfate, proton pump inhibitors, cholestyramine, and sevelamer all reduce levothyroxine absorption by direct binding or pH effects. If you take any of these, the four-hour separation rule applies, and adding empagliflozin to your routine is an opportunity to audit the full list of what you take in the morning.

Practical Counseling: The Conversation to Have With Your Prescriber

Ask for specific answers to these questions before leaving your appointment:

1. What is my current TSH, and when is my next scheduled check?
2. Should my levothyroxine dose be rechecked 6 to 8 weeks after I start Jardiance?
3. Am I taking anything else in the morning that might interfere with levothyroxine absorption?
4. Do I need a different form of contraception given that Jardiance is not safe in pregnancy?
5. If I am perimenopausal and my symptoms change, how will we distinguish thyroid under-replacement from perimenopause?

"Women taking both levothyroxine and an SGLT2 inhibitor are not at high risk for a serious drug interaction, but they are at real risk of drifting out of thyroid target range if nobody is systematically rechecking their TSH," says Dr. Elena Vasquez, MD, WomanRx Editorial Board member and reproductive endocrinologist. "The fix is straightforward: use the 30-minute separation rule, recheck TSH at 6-8 weeks, and don't assume a stable dose stays stable when you add a new cardiometabolic drug."

The Evidence Gap: What We Still Do Not Know

Women have been underrepresented in cardiology and diabetes trials for decades. The EMPA-REG OUTCOME trial enrolled approximately 28% women, meaning the cardiovascular benefit data are extrapolated largely from male participants. No trial has specifically examined empagliflozin in women with co-existing hypothyroidism, or measured serial TSH levels in women started on SGLT2 inhibitors. The levothyroxine-SGLT2 interaction guidance you will find in drug interaction databases is based on mechanistic reasoning and clinical pharmacology principles, not direct human data. That does not make the guidance wrong, but it does mean your TSH results are the best real-world data point you have, and monitoring is the most evidence-grounded action.